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Abstract
Background: Antifungal prophylaxis is currently regarded as the gold standard in situations with allo-genetic
hematopoietic stem cell transplantation (allo-HSCT). However, the epidemiological information regarding
prophylaxis of invasive fungal diseases (IFDs) is not clear in China.
Methods: We report the first large-scale (1053 patients) observational study of the prophylaxis and management of
IFDs among patients with allo-HSCT in China.
Results: The incidence rates of IFD after primary antifungal prophylaxis (PAP), secondary antifungal prophylaxis
(SAP), and non-prophylaxis were 22.7 vs. 38.6 vs. 68.6 %, respectively (P = 0.0000). The median time from
transplantation to IFD was 45 days in PAP patients, 18 days in SAP patients, and 12 days in non-prophylaxis
patients. Aspergillus spp. represents the most common type of fungal infection. Independent risk factors for IFD in
allo-HSCT patients with PAP were age, having human leukocyte antigen (HLA)-haploidentical or matched unrelated
donor, decreased albumin levels, and the use of itraconazole as the prophylactic antifungal agent. Among SAP
transplant recipients, there was no significant risk factor for IFDs. The incidence rates of overall survival (OS) in the
PAP, SAP, and no prophylaxis groups were 85.07, 78.80, and 74.82, respectively (P = 0.01).
Conclusions: This observational study indicates that prophylaxis of IFD is helpful to reduce the incidence of IFDs
and improve the OS of patients after allo-HSCT.
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Key points
This first large-scale observational study of invasive fun-
gal disease (IFD) in China indicated that prophylaxis of
IFD is helpful to improve the OS of patients after allo-
genetic hematopoietic stem cell transplantation (allo-
HSCT). For patients with a history of IFD, effective pre-
vention of IFD is particularly important because they
have higher incidence of IFD.
Background
Although the control of bacterial infections in patients
with hematological malignancies has been significantly
improved with broad-spectrum antibiotics in the past
decades, treating invasive fungal diseases (IFDs) is still a
major problem in these patients, especially in patients
undergoing allogenetic hematopoietic stem cell trans-
plantation (allo-HSCT) [1–3]. Epidemiological data from
the USA, China, and parts of Europe have shown that
the incidence of IFDs in patients after allo-HSCT has in-
creased dramatically in the past several years, substan-
tially increasing the morbidity and mortality rates [4–9].
The diagnosis and treatment guidelines for IFDs, in-
cluding some that are specific to HSCT patients, have
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been developed by academic societies in different world
regions [10–12]. Notwithstanding the guidance and new
forms of antifungal agents, treatment is often delayed
because of nonspecific disease presentation and a lack of
reliable diagnostic techniques, leading to poor clinical
outcomes. Prophylaxis of IFDs is currently regarded as
the gold standard in situations with allo-HSCT. Over the
years, different scientific societies have established a series
of recommendations for antifungal prophylaxis based on
prospective studies performed with different drugs [13–17].
However, until recently, data on the prophylaxis of
IFDs and real-world management of IFDs in patients
with allo-HSCT have been gleaned primarily from
single-center and retrospective studies in China. Here,
we report the first large-scale observational study of the
prophylaxis and management of IFDs among adults and
children who have undergone allo-HSCT in China. Data
came from the China Assessment of Antifungal Therapy
in Hematological Disease (CAESAR) study.
Methods
Study design
The CAESAR study was a multicenter, prospective, obser-
vational study performed in 35 hematology centers across
China, including two children’s hospitals. Subjects were
consecutive patients of any age with a hematological ma-
lignancy who were hospitalized during the study period ei-
ther after allogeneic or autologous HSCT or to receive
intravenous chemotherapy. The overall study methods
have been described previously [7, 18]. This observational
study was conducted as a part of the CAESAR study and
focused on the prophylaxis of IFDs in 1053 patients who
underwent allo-HSCT in 31 HSCT centers.
All patients in each study center who were hospital-
ized and had undergone allo-HSCT between January 1,
2011 and October 30, 2011 were enrolled in this study.
Data were collected by chart reviews and included the
following parameters: demographic characteristics, ante-
cedent hematologic disease, type of HSCT, conditioning
regimen, IFD risk factors, clinical features suggestive of
IFD, laboratory findings such as imaging, histopathology,
and fungal cultures, treatment outcome of IFD, and
mortality. Each IFD was categorized as proven, probable,
or possible, according to the European Organization for
Research and Treatment of Cancer/Invasive Fungal In-
fections Cooperative Group and the National Institute of
Allergy and Infectious Diseases Mycoses Study Group
(EORTC/MSG) 2008 criteria [19]. Patients were diag-
nosed as having suspected IFD if they had IFD risk fac-
tors; were observed to have symptoms, radiological
abnormalities, or indirect microbiological evidence of
fungal infection; and were treated empirically with anti-
fungal agents but could not be diagnosed with proven,
probable, or possible IFD according to the EORTC/MSG
2008 criteria [20]. Patients were followed for 6 months
after the date of transplantation; the follow-up was com-
pleted on April 30, 2012. In all, 18 patients were lost to
follow-up.
Statistical analysis
In accordance with common practice and to maximize
diagnostic accuracy, the incidence of IFD was mainly
calculated based on proven and probable cases com-
bined. The cumulative incidence was calculated as the
incidence of proven plus probable IFD for the first
187 days after transplantation, divided by the number of
cases at risk. Data were grouped according to primary
antifungal prophylaxis (PAP) or secondary antifungal
prophylaxis (SAP). PAP refers to patients without a his-
tory of fungal infection and need to be protected to
avoid fungal infection after HSCT [21]. SAP is a rational
strategy for patients with proven or probable IFD within
6 months before transplantation [22]. In particular, all
allo-HSCT patients (n = 1045) in the CAESAR study
were included in the analysis of overall survival (OS) for
comparison of the OS differences in the PAP, SAP, and no
prophylaxis groups. The characteristics of all of the allo-
HSCT patients were described in the CAESAR study [7].
Statistics were primarily descriptive and were com-
pared using analysis of variance, the Wilcoxon rank-sum
test, or the chi-squared test, as appropriate. Risk factors
for IFD were analyzed using univariate analysis followed
by multivariate logistic regression. Kaplan-Meier analysis
and the log-rank test were used to compare OS between
different groups of patients. A two-sided P value of less
than 0.05 was denoted as statistically significant. All stat-
istical analyses were performed with SAS software ver-
sion 9.1 (SAS, Cary, NC, USA).
Results
Patient characteristics and antifungal prophylaxis
regimen
A total of 1053 patients who underwent allo-HSCT were
enrolled from 31 HSCT centers across China. Their
baseline demographic and clinical characteristics at the
time of admission for transplantation are shown in
Table 1. Among them, 906 patients received prophylactic
antifungal treatment before or after transplantation. Previ-
ous IFDs were noted in 88 patients (8.4 %, 88/1053), in-
cluding 7 with proven IFDs and 81 with probable IFDs.
The average duration of antifungal prophylaxis before
HSCT was 10.9 ± 6.56 days (10.8 ± 6.57 days in the PAP
group and 12.0 ± 6.43 days in the SAP group). Single an-
tifungal agents were the most common prophylaxis regi-
men (667/818 in the PAP group and 69/88 in the SAP
group). Fluconazole (429/818, 64.9 %) and voriconazole
(32/88, 46.4 %) were the most widely used agents for
PAP and SAP, respectively (Table 1). All antifungal
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Table 1 Patient characteristics and antifungal prophylaxis regimen
Characteristic PAP (N = 818) SAP (N = 88) Non-antifungal prophylaxis (n = 147)
Age, mean (range/%)/case 28.5 (1–63) 32.2 2–58) 29.6 (4–61)
0–6 33 (4 %) 3 (3.4 %) 4 (2.7 %)
>6–16 129 (15.8 %) 10 (11.4 %) 20 (13.6 %)
>16–40 488 (59.7 %) 49 (55.7 %) 85 (57.8 %)
>40–65 168 (20.5 %) 26 (29.5 %) 38 (25.9 %)
Gender
Male 505 (61.7 %) 51 (58.0 %) 87 (59.2 %)
Female 313 (38.3 %) 37 (42.0 %) 60 (40.8 %)
E-COG
0 227 (27.8 %) 18 (20.5 %) 48 (32.7 %)
1 438 (53.5 %) 54 (61.4 %) 74 (50.3 %)
2 89 (10.9 %) 11 (12.5 %) 17 (11.6 %)
3 51 (6.2 %) 5 (5.7 %) 7 (4.8 %)
4 13 (1.6 %) – 1 (0.7 %)
Underlying disease
Acute myeloid leukemia 289 (35.3 %) 44 (50.0 %) 43 (29.3 %)
Acute lymphocytic leukemia 241 (29.5 %) 32 (36.4 %) 37 (25.2 %)
Chronic myeloid leukemia 100 (12.2 %) 3 (3.4 %) 23 (15.6 %)
Aplastic anemia 69 (8.4 %) – 13 (8.8 %)
Myelodysplastic syndrome 62 (7.6 %) 2 (2.3 %) 16 (10.9 %)
Non-Hodgkin’s lymphoma 23 (2.8 %) 4 (4.5 %) 4 (2.7 %)
Chronic lymphocytic leukemia 4 (0.5 %) – –
Multiple myeloma 2 (0.2 %) – 1 (0.7 %)
Hodgkin’s disease 2 (0.2 %) – 3 (2.0 %)
Myeloprolififerative neoplasms 2 (0.2 %) – –
Solid tumor 1 (0.1 %) – –
Hereditary and metabolic disorders 9 (1.1 %) – –
Paroxysmal nocturnal hemoglobinuria 1 (0.1 %) – 1 (0.7 %)
Othersa 13 (1.6 %) 3 (3.4 %) 6 (4.1 %)
Transplantation type
HLA-matched related (sibling) 335 (41.0 %) 35 (39.8 %) 77 (52.4 %)
Haploidentical 269 (32.9 %) 26 (29.5 %) 35 (23.8 %)
Unrelated 213 (26.0 %) 27 (30.7 %) 35 (23.8 %)
Source of stem cells
PB 417 (51.0 %) 67 (76.1 %) 105 (71.4 %)
BM + PB 348 (42.5 %) 19 (21.6 %) 20 (13.6 %)
BM 33 (4.0 %) – 7 (4.8 %)
CB 15 (1.8 %) 1 (1.1 %) 3 (2.0 %)
BM + CB 3 (0.4 %) – –
BM + PB + CB 2 (0.2 %) 1 (1.1 %) 8 (5.4 %)
Conditioning regimen
Myeloablative
Yes 729 (89.1 %) 83 (94.3 %) 124 (84.4 %)
No 89 (10.9 %) 5 (5.7 %) 23 (15.6 %)
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agents were given in accordance with the recommended
doses and schedule.
Efficacy of PAP and SAP on the prophylaxis of IFD
occurrence
In the 1053 patients, 321 (30.5 %) patients were identi-
fied as having an IFD, including 13 (1.2 %) with proven
IFD, 81 (7.7 %) with probable IFD, and 227 (21.6 %) with
possible IFD. The incidence rates of proven, probable,
and possible IFD in the PAP, SAP, and non-prophylaxis
groups were 0.7 vs. 0.0 vs. 4.8 %, 7.0 vs. 11.4 vs. 9.5 %,
and 15.0 vs. 27.3 vs. 54.4 %, respectively (Table 2). The
median time from transplantation to IFD was 45 days in
the PAP group (interquartile range (IQR), 16 to 75),
18 days in the SAP group (IQR, 7 to 26), and 12 days in
the non-prophylaxis group (IQR, 0 to 93), respectively.
Table 1 Patient characteristics and antifungal prophylaxis regimen (Continued)
Total body radiotherapy
Yes 122 (14.9 %) 23 (26.1 %) 13 (8.8 %)
No 696 (85.1 %) 65 (73.9 %) 134 (91.2 %)
Antithymocyte globulin
Yes 516 (63.1 %) 52 (59.1 %) 64 (43.5 %)
No 302 (36.9 %) 36 (40.9 %) 83 (56.5 %)
Concomitant disease 137 (16.7 %) 22 (25.0 %) 23 (15.6 %)
Cardiovascular disease 24 (2.9 %) 2 (2.3 %) 4 (2.7 %)
Diabetes 24 (2.9 %) 2 (2.3 %) 6 (4.1 %)
Viral hepatitis 22 (2.7 %) 9 (10.2 %) 4 (2.7 %)
CMV infection 1 (0.1 %) 2 (2.3 %) 1 (0.7 %)
Tuberculosis 14 (1.7 %) 3 (3.4 %) 2 (1.4 %)
Autoimmune diseases 9 (1.1 %) 1 (1.1 %) –
Othersb 61 (7.5 %) 5 (5.7 %) 8 (5.4 %)
aGVHD
I–II aGVHD 257 (31.4 %) 27 (30.7 %) 40 (27.2 %)
III–IV aGVHD 57 (7.0 %) 7 (8.0 %) 15 (10.2 %)
cGVHD
Limited 57 (7.0 %) 9 (10.3 %) 10 (6.85)
Extensive 24 (2.9 %) 2 (2.3 %) 4 (2.7 %)
Drugs for IFD prophylaxis
Single drug 667 (81.5 %) 69 (78.4 %) –
Fluconazole 429 (64.3 %) 8 (11.6 %) –
Itraconazole 103 (15.4 %) 17 (24.6 %) –
Voriconazole 71 (10.6 %) 32 (46.4 %) –
Caspofungin 4 (0.6 %) 6 (8.7 %) –
Amphotericin B 2 (0.3 %) 1 (1.4 %) –
Drug combination 151 (18.5 %) 19 (21.6 %) –
Route of administration
Oral 466 (57.0 %) 29 (33.0 %) –
Intravenous 214 (26.2 %) 37 (42.0 %) –
Oral + intravenous 138 (16.9 %) 22 (25.0 %) –
Time of prophylaxis before HSCT mean (SD), days 10.8 (6.57) 12.0 (6.43) –
E-COG Eastern Cooperative Oncology Group, PAP primary antifungal prophylaxis, SAP secondary antifungal prophylaxis, BM bone marrow, PB peripheral blood,
CB cord blood, CMV cytomegalovirus, aGVHD acute graft versus host disease, cGVHD chronic graft versus host disease, IFD invasive fungal diseases, HSCT
hematopoietic stem cell transplantation
aOthers include chronic myelomonocytic leukemia (n = 3), T lymphoblastic lymphoma leukemia (n = 2), mixed-lineage leukemia (n = 10), aggressive NK cell
leukemia (n = 3), myeloid sarcoma (n = 1), plasmablasticlymphoma (n = 3)
bOthers include infectious disease (n = 18), digestive system diseases (n = 10), cholecystolithiasis (n = 7), mouth disease (n = 8), urological diseases (n = 6), intestinal
diseases (n = 7), endocrine diseases (n = 7), surgery (n = 5), cerebrovascular disease (n = 4), tumor (n = 2)
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Characteristics of patients with IFD occurrence
Thirteen patients were diagnosed with proven IFD (6 in
the PAP group and 7 in the non-prophylaxis group), and
81 patients were diagnosed with probable IFD (57 in the
PAP group, 10 in the SAP group, and 14 in the non-
prophylaxis group). Among the 94 patients with IFD, 56
were male and 38 were female. The underlying diseases
were acute myeloid leukemia (n = 32), acute lymphocytic
leukemia (n = 32), myelodysplastic syndrome (n = 10),
chronic myeloid leukemia (n = 8), non-Hodgkin’s lymph-
oma (n = 5), aplastic anemia (n = 5), and others (n = 2).
Twenty patients received human leukocyte antigen
(HLA)-matched sibling HSCT, 42 patients received
HLA-haploidentical HSCT, and 32 patients received
HLA-matched unrelated HSCT.
Detailed data regarding the distribution of fungal path-
ogens and the methods of microbiological diagnoses of
IFDs are shown in Table 3. Of the 89 etiological patho-
gens identified in patients with proven or probable IFDs,
62 (69.7 %) were Aspergillus, including 19 that were ex-
clusively diagnosed with two positive galactomannan
tests. Unspecified Aspergillus was the most common
mold (31 cases), followed by Aspergillus flavus (5 cases),
and Aspergillus fumigatus (2 case) isolates.
The infection sites of all categories of IFD were also
analyzed. Of all the 54 infection sites identified in pa-
tients with IFDs, the most common location of infec-
tion was the lower respiratory tract (64.8 %, 35/54),
followed by blood stream infections only (13.0 %, 7/
54), central nervous system (5.6 %, 3/54), spleen
(1.9 %, 1/54), and three other sites (14.8 %, 8/54).
Further analysis showed that Aspergillus is the main
pathogen of lower respiratory tract fungal infection
(85.7 %, 30/35). In other infection sites, there was no
Table 3 Identified etiological pathogens in IFD cases
Fungal species Overall population PAP SAP Non-prophylaxis
Overall 89 55 7 27
Candida spp. 27 14 3 10
Unclassified Candida 8 5 0 3
Candida tropicalis 3 2 0 1
Candida albicans 3 2 0 1
Candida parapsilosis 3 2 0 1
Candida krusei 3 1 1 1
Candida glabrata 1 1 0 0
Candida albicans 5 1 2 2
Not specifieda 1 0 0 1
Aspergillus spp. 62 41 4 17
Positive GM tests only 19 15 1 3
Aspergillus flavus 5 3 0 2
Aspergillus versicolor 1 1 0 0
Aspergillus fumigatus 2 2 0 0
Aspergillus albicans 1 0 0 1
Mucor 1 0 0 1
Cryptococcus 1 1 0 0
Pityrosporion ovale 1 1 0 0
Not specifiedb 31 18 3 10
aIncluding cases with yeasts identified in tissue but negative cultures
bIncluding cases with hyphae identified in tissue but negative cultures
Table 2 The recurrence rates of IFD in patients from the PAP, SAP, and non-prophylaxis groups
Characteristic PAP (N = 818) SAP (N = 88) Non-prophylaxis (n = 147) P value
IFD patients 186 (22.7 %) 34 (38.6 %) 101 (68.7 %) 0.0000
Proven 6 (0.7 %) 0 (0.0 %) 7 (4.8 %)
Probable 57 (7.0 %) 10 (11.4 %) 14 (9.5 %)
Possible 123 (15.0 %) 24 (27.3 %) 80 (54.4 %)
Patients without IFD 632 (77.3 %) 54 (61.4 %) 46 (31.3 %)
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Table 4 Risk factors for proven/probable IFD among allo-HSCT patients in the PAP group












≤18 years old 9/182 4.95 0.15 0.44 2.78 (1.18–6.55) 0.02
>18 years old 54/636 8.49
Transplantation type
HLA-matched related (sibling) 10/335 2.99 0.0001
Haploidentical 31/269 11.52 0.65 6.08 (1.69–21.86) 0.01
Unrelated 22/213 10.33 0.60 8.07 (2.50–26.10) 0.00
Antithymocyte globulin
Yes 49/516 4.64 0.01 0.57 0.40 (0.13–1.24) 0.11
No 14/302 9.50
Glucocorticoidsa
Yes 58/678 8.55 0.05 0.58 1.37 (0.44–4.23) 0.58
No 5/140 3.57
GVHDb
Non-GVHD 31/428 7.24 0.15 0.40 1.63 (0.74–3.58) 0.22
aGVHD I–II 16/230 6.96
aGVHD III–IV 8/52 15.38
cGVHD local 2/60 3.33
cGVHD extensive 3/27 11.11
Prolonged, profound neutropenia
ANC > 500/mm3 1/14 7.14 0.0006
ANC < 500/mm3, <10 days 6/142 4.23 1.22 0.40 (0.04–4.33) 0.45
ANC < 500/mm3, 10–14 days 4/176 2.27 1.28 0.14 (0.01–1.73) 0.13
ANC < 500/mm3, >14 days 52/486 10.70 1.16 0.99 (0.10–9.60) 0.99
EBV viremiac








Yes 10/60 16.67 0.019 0.43 1.38 (0.59–3.24) 0.46
No 53/758 6.99
Decreased albumin
Yes 39/317 12.30 0.0001 0.31 1.98 (1.08–3.62) 0.03
No 24/501 4.79
Time of IFD prophylaxis
<35 days 33/396 8.33 0.60 0.30 1.33 (0.74–2.39) 0.35
≥35 days 30/416 7.21
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significant difference in the infection rate between As-
pergillus and Candida.
Risk factors for proven and probable IFD
The risk factors for proven and probable IFDs among
PAP and SAP transplant recipients are presented in
Tables 4 and 5. Univariate analyses revealed that HLA-
haploidentical HSCT, HLA-matched unrelated HSCT,
the use of antithymocyte globulin, prolonged profound
neutropenia (>14 days), renal impairment, decreased al-
bumin levels, and Epstein-Barr virus and cytomegalo-
virus viremia were independent risk factors for proven
Table 4 Risk factors for proven/probable IFD among allo-HSCT patients in the PAP group (Continued)
Drugs for IFD prophylaxis
Fluconazole/fluconazole + itraconazolee 39/498 7.83 0.17 0.46 1.76 (0.72–4.31) 0.21
Itraconazolee 14/103 13.59 0.53 3.14 (1.11–8.86) 0.03
Voriconazolee 2/71 2.82 0.85 0.95 (0.18–5.01) 0.95
Otherd 8/144 5.56
ANC absolute neutrophil count, EBV Epstein-Barr virus
aIncluding dexamethasone, methylprednisolone, prednisone, and hydrocortisone
bBy multivariate analysis, OR is for cGVHD extensive/aGVHD III and IV degree versus cGVHD local/aGVHD I and II degree/non-GVHD
cBy multivariate analysis, OR is for with EBV viremia versus without EBV viremia or untested/CMV viremia versus without CMV viremia or untested
dIncluding caspofungin, micafungin, amphotericin B, fluconazole + caspofungin, fluconazole +micafungin, fluconazole + voriconazole, itraconazole +micafungin,
voriconazole + caspofungin, and fluconazole + caspofungin + voriconazole
eCompared with others
The italicized data reflected significant difference
Table 5 Risk factors for proven/probable IFD among allo-HSCT patients in SAP group





Comparison (P value) SE OR (95 % CI) Comparison (P value)
Transplantation type
HLA-matched related (sibling) 1/35 2.86 0.08
Haploidentical 5/26 19.23 1.77 2.48 (0.08–79.46) 0.61
Unrelated 4/27 14.81 1.77 2.24 (0.07–72.11) 0.65
Antithymocyte globulin
Yes 9/52 17.31 0.04 1.68 2.49 (0.09–67.66) 0.59
No 1/36 2.78
Prolonged, profound neutropenia
ANC > 500/mm3 0/1 0.00 0.23 1.13 5.90 (0.65–53.89) 0.12
ANC < 500/mm3, <10 days 1/18 5.56
ANC < 500/mm3, 10–14 days 0/17 0.00
ANC < 500/mm3, >14 days 9/52 17.31
Liver impairment
Yes 5/24 20.83 0.12 0.74 2.07 (0.49–8.79) 0.33
No 5/64 7.81
Time of IFD prophylaxis
<35 days 5/40 12.50 1.00 0.76 1.10 (0.25–4.86) 0.90
≥35 days 5/48 10.42
Drugs for IFD prophylaxis
Fluconazole/itraconazole/ 3/27 11.11 1.00 0.96 0.87 (0.13–5.64) 0.88
Fluconazole + itraconazoleb
Voriconazoleb 4/32 12.50 0.91 1.50 (0.25–8.96) 0.66
Othersa 3/29 10.34
aIncluding voriconazole + caspofungin and fluconazole + caspofungin + voriconazole
bCompared with others
The italicized data reflected significant difference
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and probable IFDs in allo-HSCT patients with PAP (P <
0.05). Among the allo-HSCT patients with SAP, the use
of antithymocyte globulin was the only obviously signifi-
cant risk factor (P = 0.043).
Multivariate analyses demonstrated that independent
risk factors for proven and probable IFDs in allo-HSCT
patients with PAP were age >18 years (odds ratio (OR),
2.78; 95 % confidence interval (CI), 1.18–6.55; P < 0.05),
having an HLA-matched unrelated donor (OR, 8.07;
95 % CI, 2.50–26.10; P < 0 .01), having an HLA-
haploidentical donor (OR, 6.08; 95 % CI, 1.69–21.86; P
< 0.01), decreased albumin levels (OR, 1.98; 95 % CI,
1.08–3.62; P < 0.05), and the use of itraconazole as the
antifungal prophylactic agent (OR, 3.41; 95 % CI, 1.11–
8.86; P < 0 .05) (Table 4). Among the SAP transplant re-
cipients, there was no significant risk factor for proven
or probable IFD.
Overall antifungal therapy
A total of 321 IFD patients were provided therapeutic
antifungal treatment. A single antifungal agent was used
for treatment in 116 (36.1 %) patients; 144 (44.9 %) pa-
tients required two agents, and 61 (19.0 %) patients re-
quired three or more agents during the course of their
treatment. Among the PAP transplant recipients, itraco-
nazole (34.4 %, 64/186 in all-category IFD; 46.1 %, 29/63
in proven or probable IFD) was the most popular agent
for the initial therapy. Among the SAP and non-
prophylaxis transplant recipients, voriconazole (36.3 %,
49/135 in all-category IFD; 25.8 %, 8/31 in proven or
probable IFD) was the most common agent for the ini-
tial therapy. Whether the patients in PAP, SAP, or non-
prophylaxis groups, voriconazole as a single agent or in
combination with other agents (35.8 %, 115/321) was the
most popular agent for antifungal treatment.
The median overall treatment duration in patients
who started and completed antifungal treatment while
hospitalized was 36 days (IQR, 21–65) for PAP trans-
plant recipients, 39 days (IQR, 24–58) for SAP trans-
plant recipients, and 35 days (IQR, 20–67) for non-
prophylaxis transplant recipients. A total of 175 patients
(54.5 %, 94 in the PAP group, 20 in the SAP group, and
61 in the non-prophylaxis group) continued treatment
after leaving the hospital.
Outcomes including mortality
At the end of follow-up, 171 patients had died, resulting
in an overall mortality rate of 16.2 % (171/1053). Com-
pared with the overall study population, the mortality
rate was markedly higher in patients with proven (5/13;
38.5 %), probable (19/81; 23.5 %), or possible (58/227;
25.6 %) IFDs. Furthermore, the mortality rate among pa-
tients treated for suspected IFD despite failing to meet the
EORTC/MSG diagnostic criteria [16] (25/166; 15.1 %) was
higher than that among patients who were not suspected
of having IFD and, therefore, not treated with antifungal
agents (64/566; 11.3 %) (Fig. 1, P < 0.001). In addition, we
compared the incidence of OS in the PAP, SAP, and no
prophylaxis groups. There was a significant difference
among the three groups (85.07 vs. 78.80 vs. 74.82 %, re-
spectively, Fig. 2, P = 0.01).
Discussion
Invasive infections remain major infectious threats to
patients undergoing allo-HSCT and are associated with
high fatality rates [23–28]. The diagnosis of IFDs con-
tinues to be difficult to establish because they do not
manifest with specific clinical or radiographic signs or
symptoms [29]. In the recent years, there has been a
concerted effort to identify alternative procedures for
the future diagnosis of fungus. They include the target-
ing of fungal antigens by enzyme-linked immunosorbent
assay (ELISA) or lateral flow devices (LFDs) [30], detec-
tion of siderophores [31], and amplification of fungal nu-
cleic acids from tissue and body fluids [32] as well as
application of matrix-assisted laser desorption ionization
TOF mass spectrometry (MALDI-TOF MS) [33]. Each
of the above methods has advantages and disadvantages,
and not all of which have entered clinical practice [34].
The difficulty in obtaining a timely diagnosis as well as
the high morbidity and mortality rates associated with
IFDs provide a rationale for antifungal prophylaxis in pa-
tients undergoing allo-HSCT. Nonetheless, antifungal
prophylaxis remains a topic of some controversy, with
no clear consensus among different centers [35–37].
The CAESAR study is the first population-based and
the largest prospective observational study of the inci-
dences of IFDs in patients receiving HSCT [7]. This
Fig. 1 Overall survival of patients with proven/probable IFD, possible
IFD, or suspected IFD and who received antifungal therapy; those
with no suspected IFD and who did not receive antifungal therapy;
and those without any IFD (proven, probable, or possible)
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observational study was conducted as a part of the CAE-
SAR study and focused on the prophylaxis of IFDs in pa-
tients who underwent allo-HSCT. In the present analysis
of adults and children at risk for IFD due to allo-HSCT,
non-prophylaxis transplant recipients had a higher inci-
dence of proven/probable/possible IFD than PAP and
SAP transplant recipients at 6 months (68.6 vs. 22.7 and
38.6 %, P = 0.0000). This result was in accord with the
classic randomized clinical trials on PAP in HSCT recip-
ients and patients with hematological malignancies [38–
40]. Furthermore, the OS was significantly different
among PAP, SAP, and no prophylaxis patients. It was re-
vealed that antifungal prophylaxis was helpful to reduce
the incidence of IFD and improve the survival of pa-
tients after transplantation.
The most recently published European guidelines
pointed out that SAP should be administered to patients
with a previous IFD to prevent recurrence of the previ-
ous IFD or onset of a new IFD during a new at-risk
phase, mainly referring to a prolonged neutropenic
period induced by chemotherapy or a phase of severe
immunosuppression after allo-HSCT [16]. Several stud-
ies have reported success rates for SAP, which was
proven to be effective in preventing IFD recurrence [41,
42]. In the study, the cumulative incidence of IFD in-
creased particularly rapidly during the first month after
transplantation in the SAP group and non-prophylaxis
group, suggesting that this is a high-risk period during
which health care providers should pay particularly close
attention to signs of emerging IFD in SAP and non-
prophylaxis patients. On the contrary, the median time
of IFD occurrence in the PAP group was 45 days after
HSCT. This finding indicated that patients who had a
previous IFD and had no antifungal prophylaxis were
more likely to experience a breakthrough fungal infec-
tion in the early stage after transplantation.
As 22.7 % of patients treated with PAP and 38.6 % of
patients treated with SAP in the study went on to de-
velop proven, probable, or possible IFD, there remains
an unmet need for education about the appropriate tim-
ing and choice of antifungal agent for prophylaxis in
China. Among PAP transplant recipients, the most com-
monly prescribed prophylactic agents were fluconazole
and itraconazole, which may be less effective than posa-
conazole [43]. The use of itraconazole as the antifungal
prophylactic agent also proved the independent risk fac-
tor for IFD occurrence in our study. An update to the
cost-effectiveness of posaconazole vs. fluconazole or itra-
conazole in the prevention of IFD among neutropenic
patients in the USA has shown that posaconazole is a
cost-effective alternative to fluconazole or itraconazole
in the prevention of IFD among neutropenic patients
[44]. Among SAP transplant recipients, there was no sig-
nificant risk factor for proven or probable IFD. The
characteristics of the observational study and the small
sample size of the patients treated with SAP may be the
main reasons. Prospective and randomized studies asses-
sing the risk factors for SAP are needed in the future.
The epidemiological characteristics of IFD continue to
evolve in transplant patients. A major contributor is the
widespread use of azole prophylaxis since the early
1990s, which results in less candidiasis but more fre-
quent mold infections in hematologic malignancies [25,
45]. In most [46–48] but not all [49] cases, Aspergillus
spp. represent the most frequent cause of fungal-related
morbidity in patients with HSCT. In our study, Aspergil-
lus spp. also predominated in culture-proven or histolog-
ically proven pathogens and was more than two times as
common as Candida spp. The mortality among patients
who developed IFD (24.1 %) was almost double than
that in the overall population of HSCT patients (15.0 %),
and regression analysis confirmed that the development
of IFD is a significant independent risk factor for death,
highlighting the grave prognosis of those with IFD and
the need for a timely diagnosis and prompt treatment.
The incidence rates of invasive aspergillosis, however,
need to be interpreted with caution as establishing
this diagnosis often requires invasive procedures that
are difficult to perform in severely ill patients. The
low rate of proven/probable IFD in the present study
suggests the need to improve diagnostic techniques to
treat IFD as early and accurately as possible. Under
the existing conditions, in order to reduce the IFD-
related mortality of allo-HSCT patients, preemptive
antifungal therapy should be given to patients with
possible or suspected IFD.
The current study has several limitations. The main
limitation was its observational nature. Confounding fac-
tors cannot be controlled effectively in observational stud-
ies, frequently due to biased selection of patients or
Fig. 2 Overall survival of allo-HSCT patients receiving PAP, SAP, or
no prophylaxis
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treatment protocols. In the analysis of mortality by anti-
fungal therapy, the uncontrolled study design means that
no firm conclusions can be drawn regarding the relative
effect of different treatments. Another limitation was the
relatively short duration. The fact that the overall treat-
ment duration was not recorded in patients who were still
taking antifungal treatment after discharge from the hos-
pital further limited data analysis. A longer follow-up
would have allowed a more comprehensive analysis of pa-
tients who developed IFD after discharge. Procedures for
diagnosis, prophylaxis, and treatment of IFD were not pre-
specified in the protocol but were performed according to
usual practice and local clinical guidelines [19]. Further-
more, in some centers, diagnostic procedures were con-
ducted only among patients with suspected clinical signs
or symptoms of IFD. The observational study also meant
that the diagnosis of specific infections, although guided
by EORTC/MSG 2008 criteria, was limited to the data col-
lected according to local hospitals’ usual practice; there
was no mandatory requirement for diagnostic microbio-
logical testing or the use of a centralized laboratory to val-
idate the results.
Conclusions
In conclusion, the results of the present observational
study indicate that prophylaxis of IFD among patients
receiving allo-HSCT for hematological malignancy in
China is broadly in line with the recommended practice
and is helpful to reduce the incidence of IFD and im-
prove the OS of patients after transplantation. For pa-
tients with a history of IFD, active and effective
prevention of fungal infections is particularly important
because these patients have a higher incidence of IFD
occurrence and a shorter incubation period. Different
from the traditional view, for the allo-HSCT patients
with PAP, itraconazole was a less effective treatment
than other antifungal drugs. Aspergillus spp. represents
the most common type of fungal infection in patients
with allo-HSCT. Due to the limited diagnostic tech-
niques, it is necessary to give antifungal therapy to pa-
tients who do not meet the EORTC/MSG 2008 criteria
but show clinical evidence of fungal infection.
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